M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Ocera Therapeutics enrols first patient in Phase IIb Study of OCR-002 for treatment of acute hepatic encephalopathy
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) revealed on Wednesday the admission of the first patient in its multi-centre Phase 2b study, the 'STOP-HE' or OCR002-HE209 trial.
This is a randomised double-blind, controlled study of OCR-002 plus current standard of care versus...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives